Form 4: Altimmune Director Diane Jorkasky Reports Stock Option Grant

Director Diane Jorkasky reports the acquisition of stock options in Altimmune, Inc.

Summary

• On September 26, 2024, Diane Jorkasky, a director of Altimmune, Inc., reported the acquisition of 34,900 stock options.
• The options have an exercise price of $6.81.
• The options vest in equal monthly installments over 12 months following the grant date, contingent upon continued service.
• Jorkasky also granted power of attorney to Vipin K. Garg and Andrew Shutterly to handle SEC filings on her behalf.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock option grants, which is generally neutral in sentiment. It indicates alignment of interests between the director and shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The vesting schedule incentivizes the director to remain with the company, which could benefit stakeholders.

Key Dates